Zamtocabtagene autoleucel

Zamtocabtagene autoleucel (CART2019) is a CAR-T cell therapy developed by Miltenyi Biomedicine. Its targets are CD19 and CD20 (the sponsor names CD19-CD20). The sponsor states: tandem CAR-T approach targeting two B-cell antigens. ClinicalTrials.gov describes the intervention as: Tandem CD20-CD19-directed non-cryopreserved CAR-T cell therapy. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, in diffuse large B-cell lymphoma, primary CNS lymphoma and mantle cell lymphoma. The largest, NCT04792489, plans to enrol 315 participants with primary completion expected 2026-12-31. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.